Ruvidar®—An Effective Anti-Herpes Simplex Virus Agent
Viruses · 2025
DOI: 10.3390/v17091280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Kevin M Coombs und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada. Hauptthemen laut MEDLINE: Antiviral Agents, Herpesvirus 1, Human. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was supported by unrestricted funding provided by Theralase® Technologies, Inc. to K.M.C, Theralase® Technologies, Inc..
Abstract (Originalsprache)
Infectious agents account for millions of deaths every year. The Herpes Simplex Viruses (HSVs) are large double-stranded DNA viruses that infect more than 90% of the human population and can establish life-long latency in human hosts. Currently, effective FDA approved anti-herpetic drugs include acyclovir and later-generation derivatives (valacyclovir and famciclovir), which inhibit viral DNA synthesis. In previous work, we demonstrated that the small molecule Ruvidar® could inhibit numerous pathogenic human viruses when added to solutions of viruses both with and without light activation. In these experiments, we evaluated the ability of Ruvidar® to restrict HSV-1 replication in Vero cells, both by itself and in combination with acyclovir and metformin in the absence of light activation to mimic deep tissue. Ruvidar® successfully inhibited HSV-1 replication at significantly lower concentrations and more effectively than either acyclovir or metformin alone. We also discovered additive and synergistic anti-HSV-1 effects when combinational therapy was tested. Ruvidar® also restricted HSV-1 replication in human U251 glioblastoma astrocytoma cells, remained highly effective against acyclovir-resistant HSV-1 mutants, and protected infected cells from virus-induced cytopathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
- Theralase® Technologies Inc., 41 Hollinger Road, Toronto, ON M4B 3G4, Canada.
ORCID-Profile: Kevin M Coombs, Roger DuMoulin-White
Förderung
- This research was supported by unrestricted funding provided by Theralase® Technologies, Inc. to K.M.C
- Theralase® Technologies, Inc.
Zitieren
APA
Coombs, K. M., DuMoulin-White, R., & Mandel, A. (2025). Ruvidar®—An Effective Anti-Herpes Simplex Virus Agent. Viruses. https://doi.org/10.3390/v17091280
Vancouver
Coombs KM, DuMoulin-White R, Mandel A. Ruvidar®—An Effective Anti-Herpes Simplex Virus Agent. Viruses. 2025. doi:10.3390/v17091280
BibTeX
@article{Coombs2025,
author = {Coombs, Kevin M and DuMoulin-White, Roger and Mandel, Arkady},
title = {Ruvidar®—An Effective Anti-Herpes Simplex Virus Agent},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17091280}
}
EUVIMED